Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Prolactinoma 5Pituitary Neoplasms 4Polycystic Ovary Syndrome 3Hyperprolactinemia 2Recurrence 1Prolactin Deficiency, Isolated 1Pituitary ACTH Hypersecretion 1Ovarian Hyperstimulation Syndrome 1Heart Valve Diseases 1Breast Neoplasms 1Adenoma 1ACTH-Secreting Pituitary Adenoma 1

Interventions

Cyclophosphamide 115Dexamethasone 70fludarabine phosphate 57Cytarabine 56fludarabine 52Rituximab 51Peripheral Blood Stem Cell Transplantation 40Etoposide 40Gemcitabine 39Lenalidomide 38pembrolizumab 33Radiotherapy 33Busulfan 33Filgrastim 32Carboplatin 31Methotrexate 30Cyclosporine 29Cisplatin 29Bortezomib 29Mycophenolic Acid 28Melphalan 28venetoclax 27Paclitaxel 26Whole-Body Irradiation 24Antilymphocyte Serum 23Temozolomide 22Granulocyte Colony-Stimulating Factor 20Calcium Dobesilate 20Bevacizumab 20Tacrolimus 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Recurrence × Cabergoline × Clear all
NCT03457389 2020-03-18

Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma

Seoul National University Hospital

Phase NA Unknown
68 enrolled
Endocrine

Pituitary Neoplasms, Recurrence, Prolactinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡